28295933|t|High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography - guided biopsy as compared with prostatectomy specimens
28295933|a|To determine the utility of our transgluteal magnetic resonance imaging (MRI)- guided prostate biopsy approach. A total of 960 biopsy series, taken within the period of 1 year, were evaluated, including 301 MRI-guided and 659 transrectal ultrasonography (TRUS)- guided biopsies. The positivity rate and proportion of high grade cancers were significantly higher in MRI-guided than in TRUS - guided biopsies. Of 301 MRI-guided biopsies, 65.4% contained cancer while 57.2% of 659 TRUS biopsies contained cancer (P = 0.016). Gleason grade 3 + 3 = 6 disease was observed in 16.8% of 197 MRI-guided and in 36.1% of 377 TRUS - guided biopsies (P < 0.001). There was also a markedly higher quantity of cancer tissue in MRI-guided biopsies. In all cancers, the mean cancer surface area was 64.8 ± 51.6 mm(2) in MRI-guided biopsies as compared with 23.0 ± 31.4 mm(2) in non-MRI-guided biopsies (P < 0.001). With respect to the tissue quantity, superiority of MRI-guided biopsy was highest in Gleason grade 3 + 3 = 6 cancers (20.9 ± 27.9 vs 5.1 ± 10.2 mm(2); P < 0.001) and in Gleason grade 3 + 4 = 7 cancers (59.7 ± 38.0 vs 17.7 ± 18.4 mm(2); P < 0.001). Comparison of biopsy Gleason grades with findings in prostatectomy specimens was possible in 80 patients with MRI-guided and in 170 patients with non-MRI-guided biopsies. This comparison showed a very high but almost identical concordance of TRUS - and MRI-guided biopsies with the prostatectomy specimen findings. With both approaches, undetected high-risk cancers were present in ~10% of patients with low-risk biopsy results. A significant difference was observed, however, in the proportion of patients who had clinically insignificant cancers and who underwent surgery. The proportion of patients with Gleason grade 3 + 3 = 6 carcinoma in their prostatectomy specimen was 11.2% in the post - TRUS biopsy cohort, but only 2.5% in the post - MRI biopsy cohort (P = 0.021). MRI-guided transgluteal prostate biopsy has a high detection rate for high-risk carcinomas, while the risk of detecting clinically insignificant carcinomas appears to be reduced. This may by itself lead to a reduction of unnecessary prostatectomies. Overtreatment may be further avoided by better applicability of molecular testing to MRI-guided biopsies because of the excessive amount of tissue available for analysis, especially in patients with potential low-risk carcinomas.
28295933	0	4	High	T080	C0205250
28295933	20	28	findings	T033	C0243095
28295933	29	37	obtained	T169	C1301820
28295933	43	55	transgluteal	T082	C0444462
28295933	56	82	magnetic resonance imaging	T060	C0024485
28295933	89	116	transrectal ultrasonography	T060	C0373345
28295933	119	132	guided biopsy	T060	C0456900
28295933	136	144	compared	T052	C1707455
28295933	150	163	prostatectomy	T061	C0033573
28295933	164	173	specimens	T077	C2347026
28295933	191	198	utility	T169	C0457083
28295933	206	218	transgluteal	T082	C0444462
28295933	219	245	magnetic resonance imaging	T060	C0024485
28295933	247	250	MRI	T060	C0024485
28295933	253	275	guided prostate biopsy	T060	C0456852
28295933	301	307	biopsy	T060	C0005558
28295933	308	314	series	T081	C0205549
28295933	333	339	period	T079	C1948053
28295933	345	349	year	T079	C0439234
28295933	356	365	evaluated	T058	C0220825
28295933	381	391	MRI-guided	T060	C0456854
28295933	400	427	transrectal ultrasonography	T060	C0373345
28295933	429	433	TRUS	T060	C0373345
28295933	436	451	guided biopsies	T060	C0456900
28295933	457	467	positivity	T033	C1446409
28295933	468	472	rate	T081	C1521828
28295933	477	487	proportion	T081	C1709707
28295933	491	501	high grade	T033	C1962917
28295933	502	509	cancers	T191	C0006826
28295933	515	535	significantly higher	T081	C4055637
28295933	539	549	MRI-guided	T060	C0456854
28295933	558	562	TRUS	T060	C0373345
28295933	565	580	guided biopsies	T060	C0456900
28295933	589	608	MRI-guided biopsies	T060	C0456854
28295933	626	632	cancer	T191	C0006826
28295933	652	656	TRUS	T060	C0373345
28295933	657	665	biopsies	T060	C0456900
28295933	666	675	contained	T169	C0332256
28295933	676	682	cancer	T191	C0006826
28295933	684	685	P	T081	C1709380
28295933	696	709	Gleason grade	T033	C3203027
28295933	732	740	observed	T169	C1441672
28295933	757	767	MRI-guided	T060	C0456854
28295933	788	792	TRUS	T060	C0373345
28295933	795	810	guided biopsies	T060	C0456900
28295933	812	813	P	T081	C1709380
28295933	850	856	higher	T080	C0205250
28295933	857	865	quantity	T081	C1265611
28295933	869	882	cancer tissue	T191	C0027656
28295933	886	905	MRI-guided biopsies	T060	C0456854
28295933	914	921	cancers	T191	C0006826
28295933	932	938	cancer	T191	C0006826
28295933	939	951	surface area	T082	C0205146
28295933	977	996	MRI-guided biopsies	T060	C0456854
28295933	1060	1061	P	T081	C1709380
28295933	1092	1098	tissue	T191	C0027656
28295933	1099	1107	quantity	T081	C1265611
28295933	1109	1120	superiority	T082	C1282910
28295933	1124	1141	MRI-guided biopsy	T060	C0456854
28295933	1146	1153	highest	T080	C1522410
28295933	1157	1170	Gleason grade	T033	C3203027
28295933	1181	1188	cancers	T191	C0006826
28295933	1223	1224	P	T081	C1709380
28295933	1241	1254	Gleason grade	T033	C3203027
28295933	1265	1272	cancers	T191	C0006826
28295933	1308	1309	P	T081	C1709380
28295933	1320	1330	Comparison	T052	C1707455
28295933	1334	1340	biopsy	T060	C0005558
28295933	1341	1355	Gleason grades	T033	C3203027
28295933	1361	1369	findings	T033	C0243095
28295933	1373	1386	prostatectomy	T061	C0033573
28295933	1387	1396	specimens	T077	C2347026
28295933	1416	1424	patients	T101	C0030705
28295933	1430	1440	MRI-guided	T060	C0456854
28295933	1452	1460	patients	T101	C0030705
28295933	1496	1506	comparison	T052	C1707455
28295933	1521	1525	high	T080	C0205250
28295933	1537	1546	identical	T080	C0205280
28295933	1562	1566	TRUS	T060	C0373345
28295933	1573	1592	MRI-guided biopsies	T060	C0456854
28295933	1602	1615	prostatectomy	T061	C0033573
28295933	1616	1624	specimen	T077	C2347026
28295933	1625	1633	findings	T033	C0243095
28295933	1657	1667	undetected	T033	C0442737
28295933	1668	1685	high-risk cancers	T191	C1512441
28295933	1691	1698	present	T033	C0150312
28295933	1710	1718	patients	T101	C0030705
28295933	1724	1732	low-risk	T081	C3538919
28295933	1733	1739	biopsy	T060	C0005558
28295933	1740	1747	results	T034	C0456984
28295933	1751	1762	significant	T078	C0750502
28295933	1778	1786	observed	T169	C1441672
28295933	1804	1814	proportion	T081	C1709707
28295933	1818	1826	patients	T101	C0030705
28295933	1835	1845	clinically	T080	C0205210
28295933	1846	1859	insignificant	T033	C1273937
28295933	1860	1867	cancers	T191	C0006826
28295933	1886	1893	surgery	T061	C0543467
28295933	1899	1909	proportion	T081	C1709707
28295933	1913	1921	patients	T101	C0030705
28295933	1927	1940	Gleason grade	T033	C3203027
28295933	1951	1960	carcinoma	T191	C0007097
28295933	1970	1983	prostatectomy	T061	C0033573
28295933	1984	1992	specimen	T077	C2347026
28295933	2010	2014	post	T079	C0687676
28295933	2017	2021	TRUS	T060	C0373345
28295933	2022	2028	biopsy	T060	C0005558
28295933	2029	2035	cohort	T098	C0599755
28295933	2058	2062	post	T079	C0687676
28295933	2065	2075	MRI biopsy	T060	C0456854
28295933	2076	2082	cohort	T098	C0599755
28295933	2084	2085	P	T081	C1709380
28295933	2096	2106	MRI-guided	T060	C0456854
28295933	2107	2119	transgluteal	T082	C0444462
28295933	2120	2135	prostate biopsy	T060	C0194804
28295933	2142	2146	high	T080	C0205250
28295933	2147	2156	detection	T061	C1511790
28295933	2157	2161	rate	T081	C1521828
28295933	2166	2186	high-risk carcinomas	T191	C1512441
28295933	2198	2202	risk	T078	C0035647
28295933	2206	2215	detecting	T061	C1511790
28295933	2216	2226	clinically	T080	C0205210
28295933	2227	2240	insignificant	T033	C1273937
28295933	2241	2251	carcinomas	T191	C0007097
28295933	2266	2273	reduced	T080	C0392756
28295933	2304	2313	reduction	T080	C0392756
28295933	2317	2344	unnecessary prostatectomies	T061	C0376707
28295933	2346	2359	Overtreatment	T058	C4046039
28295933	2410	2427	molecular testing	T059	C0752096
28295933	2431	2450	MRI-guided biopsies	T060	C0456854
28295933	2466	2475	excessive	T080	C0442802
28295933	2476	2482	amount	T081	C1265611
28295933	2486	2492	tissue	T191	C0027656
28295933	2493	2502	available	T169	C0470187
28295933	2507	2515	analysis	T062	C0936012
28295933	2531	2539	patients	T101	C0030705
28295933	2545	2554	potential	T080	C3245505
28295933	2555	2563	low-risk	T081	C3538919
28295933	2564	2574	carcinomas	T191	C0007097